JP2019521988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521988A5 JP2019521988A5 JP2018565843A JP2018565843A JP2019521988A5 JP 2019521988 A5 JP2019521988 A5 JP 2019521988A5 JP 2018565843 A JP2018565843 A JP 2018565843A JP 2018565843 A JP2018565843 A JP 2018565843A JP 2019521988 A5 JP2019521988 A5 JP 2019521988A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- composition according
- ezh2 inhibitor
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 10
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 229940123189 CD40 agonist Drugs 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 210000001102 germinal center b cell Anatomy 0.000 claims 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034296A JP2023071905A (ja) | 2016-06-17 | 2023-03-07 | 癌を処置するためのｅｚｈ２阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351878P | 2016-06-17 | 2016-06-17 | |
| US62/351,878 | 2016-06-17 | ||
| PCT/US2017/037973 WO2017218953A1 (en) | 2016-06-17 | 2017-06-16 | Ezh2 inhibitors for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034296A Division JP2023071905A (ja) | 2016-06-17 | 2023-03-07 | 癌を処置するためのｅｚｈ２阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521988A JP2019521988A (ja) | 2019-08-08 |
| JP2019521988A5 true JP2019521988A5 (enExample) | 2020-07-27 |
Family
ID=60664319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565843A Pending JP2019521988A (ja) | 2016-06-17 | 2017-06-16 | 癌を処置するためのｅｚｈ２阻害剤 |
| JP2023034296A Pending JP2023071905A (ja) | 2016-06-17 | 2023-03-07 | 癌を処置するためのｅｚｈ２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034296A Pending JP2023071905A (ja) | 2016-06-17 | 2023-03-07 | 癌を処置するためのｅｚｈ２阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11147819B2 (enExample) |
| EP (1) | EP3471830A4 (enExample) |
| JP (2) | JP2019521988A (enExample) |
| MA (1) | MA45406A (enExample) |
| WO (1) | WO2017218953A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| EP4272742A1 (en) * | 2014-11-17 | 2023-11-08 | Epizyme Inc | Epz-6438 for use in a method for treating cancer |
| JP7121660B2 (ja) | 2016-06-01 | 2022-08-18 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| NZ766447A (en) | 2018-01-31 | 2021-12-24 | Mirati Therapeutics Inc | Prc2 inhibitors |
| JP2021517127A (ja) * | 2018-03-06 | 2021-07-15 | アンスティテュ キュリィ | 癌併用療法における使用のためのｓｅｔｄｂ１ヒストンメチルトランスフェラーゼの阻害剤 |
| WO2020219448A1 (en) | 2019-04-22 | 2020-10-29 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| JP7541538B2 (ja) | 2019-06-05 | 2024-08-28 | ミラティ セラピューティクス，インク． | 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| JP2023527116A (ja) * | 2020-05-28 | 2023-06-27 | エピザイム インコーポレイテッド | がんを治療するためのｅｚｈ２阻害剤の使用 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| EA023788B1 (ru) | 2010-05-07 | 2016-07-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные индола и фармацевтические композиции на их основе |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| WO2013120104A2 (en) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2953941B1 (en) | 2013-02-11 | 2017-04-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR102587175B1 (ko) | 2012-03-12 | 2023-10-06 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| JP6340361B2 (ja) | 2012-04-13 | 2018-06-06 | エピザイム，インコーポレイティド | がんを処置するための組合せ治療 |
| IL296199B2 (en) | 2012-04-13 | 2024-12-01 | Eisai R&D Man Co Ltd | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| AU2013331380B2 (en) | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
| WO2014092905A1 (en) | 2012-12-10 | 2014-06-19 | Children's Medical Center Corporation | Methods and assays for combination treatment of cancer |
| WO2014100646A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| EP2970281A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BENZOL COMPOUNDS |
| WO2014144747A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015052147A1 (en) | 2013-10-09 | 2015-04-16 | Roche Diagnostics Gmbh | Methods and compositions for detecting mutation in the human ezh2 gene |
| AU2014337300B2 (en) | 2013-10-16 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Hydrochloride salt form for EZH2 inhibition |
| US20160228447A1 (en) | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
| KR20210117347A (ko) * | 2013-12-06 | 2021-09-28 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| JP6345787B2 (ja) | 2013-12-20 | 2018-06-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗ａｎｇ２抗体とｃｄ４０アゴニストとの併用療法 |
| LT3157527T (lt) * | 2014-06-17 | 2023-07-25 | Epizyme, Inc. | Ezh2 inhibitoriai, skirti limfomos gydymui |
| US20170217941A1 (en) | 2014-06-25 | 2017-08-03 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| MX394629B (es) | 2014-10-16 | 2025-03-24 | Epizyme Inc | Método para tratar el cáncer. |
| EP4272742A1 (en) | 2014-11-17 | 2023-11-08 | Epizyme Inc | Epz-6438 for use in a method for treating cancer |
| MX391720B (es) | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| CA2988816A1 (en) * | 2015-06-10 | 2016-12-15 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| US20200093815A1 (en) | 2015-07-28 | 2020-03-26 | Constellation Pharmaceuticals, Inc. | Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| KR20180054793A (ko) | 2015-09-25 | 2018-05-24 | 에피자임, 인코포레이티드 | 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법 |
| EP4309738A3 (en) | 2015-10-06 | 2024-07-17 | Epizyme, Inc. | Method of treating medulloblastoma with an ezh2 inhibitor |
| US20190070188A1 (en) | 2015-11-06 | 2019-03-07 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
| EP3386513A2 (en) | 2015-12-07 | 2018-10-17 | Epizyme Inc | Inhibitors of ezh2 and methods of use thereof |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| WO2017139404A1 (en) | 2016-02-08 | 2017-08-17 | Epizyme, Inc. | Methods of treating cancer |
| JP7121660B2 (ja) | 2016-06-01 | 2022-08-18 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
-
2017
- 2017-06-16 US US16/310,597 patent/US11147819B2/en not_active Expired - Fee Related
- 2017-06-16 WO PCT/US2017/037973 patent/WO2017218953A1/en not_active Ceased
- 2017-06-16 EP EP17814211.3A patent/EP3471830A4/en not_active Withdrawn
- 2017-06-16 JP JP2018565843A patent/JP2019521988A/ja active Pending
- 2017-06-16 MA MA045406A patent/MA45406A/fr unknown
-
2021
- 2021-09-14 US US17/474,202 patent/US20220105098A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034296A patent/JP2023071905A/ja active Pending
- 2023-10-27 US US18/496,074 patent/US20240180919A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521988A5 (enExample) | ||
| JP2018524298A5 (enExample) | ||
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| JP2015537020A5 (enExample) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2005506352A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| JP2018528192A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
| RU2014108885A (ru) | Ингибирование транзиторного рецепторного потенциала ионного канала trpa1 | |
| RU2014112108A (ru) | Составы с производными децитабина | |
| JP2018502101A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| JP2019535723A5 (enExample) | ||
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| CA2539349A1 (en) | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| RU2008136762A (ru) | Циклические сульфоны как ингибиторы васе | |
| JP2016515550A5 (enExample) |